Publicaciones en colaboración con investigadores/as de Oslo University Hospital (17)

2024

  1. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  2. PD-1H/VISTA mediates immune evasion in acute myeloid leukemia

    The Journal of clinical investigation, Vol. 134, Núm. 3

2022

  1. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  2. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

    Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43

  3. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  4. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

    Gynecologic Oncology, Vol. 164, Núm. 3, pp. 498-504

2021

  1. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  2. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

    The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 613-621

  3. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  4. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

2020

  1. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    Obstetrical and Gynecological Survey

  2. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    International Journal of Gynecological Cancer

  3. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic

    Radiotherapy and Oncology

2019

  1. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

    Gynecologic Oncology, Vol. 152, Núm. 1, pp. 53-60

2017

  1. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

    Gynecologic Oncology, Vol. 144, Núm. 1, pp. 65-71

2016

  1. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer

    New England Journal of Medicine, Vol. 375, Núm. 22, pp. 2154-2164